ATE538781T1 - Neue verwendung von peptidverbindungen zur behandlung von dyskinesie - Google Patents

Neue verwendung von peptidverbindungen zur behandlung von dyskinesie

Info

Publication number
ATE538781T1
ATE538781T1 AT05750546T AT05750546T ATE538781T1 AT E538781 T1 ATE538781 T1 AT E538781T1 AT 05750546 T AT05750546 T AT 05750546T AT 05750546 T AT05750546 T AT 05750546T AT E538781 T1 ATE538781 T1 AT E538781T1
Authority
AT
Austria
Prior art keywords
peptide compounds
new use
treat dyskinesia
dyskinesia
treat
Prior art date
Application number
AT05750546T
Other languages
English (en)
Inventor
Thomas Stoehr
Original Assignee
Ucb Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Pharma Gmbh filed Critical Ucb Pharma Gmbh
Application granted granted Critical
Publication of ATE538781T1 publication Critical patent/ATE538781T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
AT05750546T 2004-05-18 2005-05-17 Neue verwendung von peptidverbindungen zur behandlung von dyskinesie ATE538781T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57193204P 2004-05-18 2004-05-18
EP04011833A EP1604654A1 (de) 2004-05-18 2004-05-18 Neue Verwendung von Peptidverbindungen zur Behandlung von Dyskynesien
PCT/EP2005/005355 WO2005110390A1 (en) 2004-05-18 2005-05-17 Novel use of peptide compounds for treating dyskinesia

Publications (1)

Publication Number Publication Date
ATE538781T1 true ATE538781T1 (de) 2012-01-15

Family

ID=34925049

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05750546T ATE538781T1 (de) 2004-05-18 2005-05-17 Neue verwendung von peptidverbindungen zur behandlung von dyskinesie

Country Status (12)

Country Link
US (1) US7416864B2 (de)
EP (2) EP1604654A1 (de)
JP (1) JP4938656B2 (de)
AT (1) ATE538781T1 (de)
AU (1) AU2005244440A1 (de)
BR (1) BRPI0511291A (de)
CA (1) CA2565051C (de)
EA (1) EA200602129A1 (de)
ES (1) ES2380510T3 (de)
MX (1) MXPA06013300A (de)
UA (1) UA86808C2 (de)
WO (1) WO2005110390A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2262567T3 (es) * 2001-03-20 2006-12-01 Schwarz Pharma Ag Nuevo uso de una clase peptidica de compuesto para tratamiento del dolor inflamatorio no neuropatico.
DE60100055T2 (de) * 2001-03-21 2003-07-24 Sanol Arznei Schwarz Gmbh Neue Verwendung einer Klasse von Peptidverbindungen zur Behandlung von Allodynie oder andere Arten von chronischen oder Phantomschmerzen
EP1689378B1 (de) * 2003-12-02 2009-04-15 Schwarz Pharma Ag Neue verwendung von peptidverbindungen zur behandlung ovn zentralen neuropathischen schmerzen
EP1579858A1 (de) * 2004-03-26 2005-09-28 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen zur Behandlung von diabetishen Neuropathie
US20100256179A1 (en) * 2004-03-26 2010-10-07 Ucb Pharma Gmbh Combination therapy for pain in painful diabetic neuropathy
US20070042969A1 (en) * 2004-03-26 2007-02-22 Srz Properties, Inc. Combination therapy for pain in painful diabetic neuropathy
EP1734980A1 (de) 2004-04-16 2006-12-27 Schwarz Pharma Ag Verwendung peptidähnlicher verbindungen zur vorbeugung und behandlung chronischer kopfschmerzen
EP1604655A1 (de) * 2004-06-09 2005-12-14 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen zur Behandlung von Trigeminusneuralgie
EP1604656A1 (de) 2004-06-09 2005-12-14 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen zur Behandlung von amyotropher Lateralsklerose (ALS)
US7427601B2 (en) * 2004-06-24 2008-09-23 Schwarz Pharma Ag Method for treating tremor
CA2573125A1 (en) * 2004-08-27 2006-03-02 Schwarz Pharma Ag Novel use of peptide compounds for treating bone cancer pain, chemotherapy-and nucleoside-induced pain
EP1642889A1 (de) * 2004-10-02 2006-04-05 Schwarz Pharma Ag Verbessertes Syntheseschema für Lacosamid
US20060252749A1 (en) * 2005-01-28 2006-11-09 Srz Properties, Inc. Lacosamide for add-on therapy of psychosis
EP1754476A1 (de) * 2005-08-18 2007-02-21 Schwarz Pharma Ag Lacosamid (SPM 927) zur Behandlung von Myalgien, z.B. Fibromyalgie
US20070043120A1 (en) * 2005-08-18 2007-02-22 Bettina Beyreuther Therapeutic combination for painful medical conditions
US20070048372A1 (en) * 2005-08-18 2007-03-01 Srz Properties, Inc. Method for treating non-inflammatory osteoarthritic pain
NZ567108A (en) * 2005-12-20 2011-10-28 Nps Pharma Inc Fluorinated compounds
US7902401B2 (en) * 2006-12-14 2011-03-08 Nps Pharmaceuticals, Inc. Fluorinated compounds
EA019757B1 (ru) * 2006-06-15 2014-06-30 ЮСиБи ФАРМА ГМБХ Фармацевтическая композиция с синергетическим противосудорожным эффектом
CN101466390B (zh) * 2006-06-15 2014-03-12 优时比制药有限公司 用于治疗难治性癫痫持续状态的肽类化合物
EP1873527A1 (de) * 2006-06-30 2008-01-02 Schwarz Pharma Ag Verfahren zur Identifizierung von CRMP-Modulatoren
WO2008070994A1 (en) * 2006-12-14 2008-06-19 Nps Pharmaceuticals, Inc. Use of d-serine derivatives for the treatment of anxiety disorders
US20100260716A1 (en) 2007-10-23 2010-10-14 Ucb Pharma Gmbh Compounds for treating demyelination conditions
US8829033B2 (en) 2009-09-23 2014-09-09 The University Of North Carolina At Chapel Hill N-benzylamide substituted derivatives of 2-(acylamido)acetic acid and 2-(acylamido)propionic acids: potent neurological agents
CA2817654A1 (en) 2010-12-02 2012-06-07 Ucb Pharma Gmbh Once daily formulation of lacosamide
EP2468261A1 (de) 2010-12-02 2012-06-27 UCB Pharma GmbH Formulierung von Lacosamid

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU84891A1 (fr) * 1983-06-30 1985-03-29 Continental Pharma Derives de l'acide 2-aminoacetique,leur preparation et utilisation ainsi que compositions pharmaceutiques contenant ces derives
US5378729A (en) 1985-02-15 1995-01-03 Research Corporation Technologies, Inc. Amino acid derivative anticonvulsant
ATE111460T1 (de) * 1990-06-15 1994-09-15 Synthelabo 2-(aminoalkyl)-5-(arylalkyl)1,3-dioxanderivate, ihre herstellung und ihre anwendung in der therapeutik.
US5773475A (en) * 1997-03-17 1998-06-30 Research Corporation Technologies, Inc. Anticonvulsant enantiomeric amino acid derivatives
US6048899A (en) * 1997-03-17 2000-04-11 Research Corporation Tech., Inc. Anticonvulsant enantiomeric amino acid derivatives
US5866585A (en) * 1997-05-22 1999-02-02 Synchroneuron, Llc Methods of treating tardive dyskinesia using NMDA receptor antagonists
EP0900567A3 (de) * 1997-09-05 2001-05-02 Pfizer Products Inc. Quinazolin-4-on AMPA Antagonisten zur Behandlung von motorischen Fehlfunktionen verbunden mit Dopaminagonist Therapie
ATE476971T1 (de) * 2000-08-25 2010-08-15 Res Corp Technologies Inc Aminosäure enthaltende antikonvulsiva zur behandlung von zwangsstörungen
ES2262567T3 (es) * 2001-03-20 2006-12-01 Schwarz Pharma Ag Nuevo uso de una clase peptidica de compuesto para tratamiento del dolor inflamatorio no neuropatico.
DE60100055T2 (de) 2001-03-21 2003-07-24 Sanol Arznei Schwarz Gmbh Neue Verwendung einer Klasse von Peptidverbindungen zur Behandlung von Allodynie oder andere Arten von chronischen oder Phantomschmerzen

Also Published As

Publication number Publication date
US20050261204A1 (en) 2005-11-24
MXPA06013300A (es) 2007-02-22
BRPI0511291A (pt) 2007-12-04
EP1753414A1 (de) 2007-02-21
EP1604654A1 (de) 2005-12-14
EA200602129A1 (ru) 2007-04-27
AU2005244440A1 (en) 2005-11-24
ES2380510T3 (es) 2012-05-14
CA2565051A1 (en) 2005-11-24
UA86808C2 (ru) 2009-05-25
JP2007538037A (ja) 2007-12-27
US7416864B2 (en) 2008-08-26
JP4938656B2 (ja) 2012-05-23
EP1753414B1 (de) 2011-12-28
CA2565051C (en) 2013-01-22
WO2005110390A1 (en) 2005-11-24

Similar Documents

Publication Publication Date Title
ATE538781T1 (de) Neue verwendung von peptidverbindungen zur behandlung von dyskinesie
DE602004017736D1 (de) Verwendung von rapamycin und dessen derivaten zur behandlung von knochenverlust
ATE544449T1 (de) Neue verwendung von peptidverbindungen zur behandlung von amyothropher lateralsklerose
ATE513550T1 (de) Verwendung eines ibat-hemmers zur behandlung oder vorbeugung von verstopfung
TW200701982A (en) Novel use of peptide compounds for treating pain in trigeminal neuralgia
ATE534379T1 (de) Neue verwendung von peptid-verbindungen zur behandlung von muskelschmerzen
UA88166C2 (ru) Применение пептидных соединений для лечения эссенцильного дрожания и других синдромов дрожания
ATE470439T1 (de) Verwendung von hif 1alfa modulatoren zur behandlung von krebs
ATE308364T1 (de) Verwendung von cyanochinolinen zur behandlung oder inhibierung von dickdarmpolypen
DE602005026508D1 (de) Monozyklische heterozyklen als kinase-hemmer
BRPI0519424A2 (pt) composiÇÕes e mÉtodos para tratamento de distérbios de proliferaÇço celular
ATE445402T1 (de) Neue verwendung von pde5-hemmern
ATE553090T1 (de) Cathepsincysteinproteasehemmer
ATE410235T1 (de) Behandlung von ballastwasser
DE602005014632D1 (de) Pyrrol- bzw. imidazolamide zur behandlung von obesitas
ATE551054T1 (de) Verfahren und zusammensetzungen zur behandlung von nephrogenem diabetes insipidus
DE60213365D1 (de) Verwendung von mglur5 antagonisten zur behandlung von pruritischen zuständen
DE60033569D1 (de) Neue verwendung von prodigiosin zur behandlung von diabetes mellitus
TW200701983A (en) Novel use of peptide compounds for treating dyskinesia
MY139442A (en) Novel use of peptide compounds for treating dyskinesia
ATE358495T1 (de) Verwendung von einem chrysanthellum indicum extrakt zur behandlung der akne rosacea
ATE423780T1 (de) Makrozyclen zur behandlung von krebserkrankungen
DE60321377D1 (de) Verwendung von levocetirizin zur behandlung von persistierender allergischer rhinitis
ATE432359T1 (de) Modulation der s6-kinaseaktivität zur behandlung von adipositas
DE502004009491D1 (de) Thiaepothilone zur behandlung von krebserkrankungen